Impact of Acquired FXIII Deficiency on Morbidity and Mortality

Completed

• Conditions: Acquired Factor XIII Deficiency Disease
• Interventions: Other: Data collection

• Registration Number: NCT04416594
• Lead Sponsor: Patricia Duque González

Brief Summary

Observational prospective study aiming to assess acquired FXIII deficiency implications in morbidity and mortality

Detailed Description

All patients admitted to a large tertiary hospital with FXIII levels below 70% during their hospital stay are assessed. Data regarding patient background, blood transfusion, morbidity and mortality is registered.

Study Timeline

• Study Start: 2019-09-10
• Primary Completion: 2020-02-12
• Study Completion: 2020-05-18
• Study First Submitted: 2020-05-26
• Status Verified: 2020-06
• Study First Submitted QC: 2020-06-01
• Last Update Submitted: 2020-06-03
• Study First Posted: 2020-06-04
• Last Update Posted: 2020-06-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• FXIII levels < 70%

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Factor XIII deficiency	Data collection	Patients admitted to hospital with FXIII levels below 70% during their hospital stay

Primary Outcome Measures

Name	Time	Method
Cut-Point levels of FXIII	2 years	The investigators aim to find a laboratory parameter, a cut-point plasma level of FXIII, to identify an increased in morbidity and mortality in a mixed cohort of hospitalized patients

Trial Locations

Locations (1)

Gregorio Marañon Hospital; 🇪🇸 Madrid, Spain